CAMBRIDGE, Mass.–(BUSINESS WIRE)–Compass Therapeutics, a biotechnology company focused on drugging the human immune synapse to treat human diseases, will present at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 in New York, NY.
The company’s co-founder and chief executive officer, Thomas Schuetz, M.D., Ph.D., will be giving a corporate overview and an update on the company’s pipeline progress, including the Phase 1 trial of CTX-471, a fully human agonistic antibody of CD137, and the company’s second clinical candidate, a novel PD-1/PD-L1 bispecific, which has a unique mechanism of action.
The presentation details are:
Date: Tuesday, December 3
Time: 3:30 p.m. EST
Location: Harlem Track, Kennedy 2, 4th Floor at The Palace Lotte, New York, NY.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.